ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
NovoCure Limited (NVCR) stock declined over -2.89%, trading at $16.49 on NASDAQ, down from the previous close of $16.98. The stock opened at $16.25, fluctuating between $15.92 and $16.80 in the recent session.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Employees | 1488 |
Beta | 0.63 |
Sales or Revenue | $509.34M |
5Y Sales Change% | 0.772% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Medical - Instruments & Supplies |
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com